Ascelia Pharma (ACE) Resumen de Acciones
Ascelia Pharma AB (publ), empresa biotecnológica, se centra en tratamientos oncológicos huérfanos en Suecia. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ACE Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Ascelia Pharma AB (publ)
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | SEK 0.62 |
| Máximo en las últimas 52 semanas | SEK 3.98 |
| Mínimo de 52 semanas | SEK 0.46 |
| Beta | 0.85 |
| Cambio en 1 mes | 8.17% |
| Variación en 3 meses | -79.47% |
| Cambio de 1 año | -84.07% |
| Variación en 3 años | -85.30% |
| Variación en 5 años | -97.93% |
| Variación desde la OPV | -97.50% |
Noticias y actualizaciones recientes
ACE: FDA Type A Meeting Will Shape Long-Term Upside Potential
Analysts have trimmed their price target on Ascelia Pharma from SEK 2.87 to SEK 2.40, reflecting updated assumptions around discount rates, profit expectations and future P/E levels. What's in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on the New Drug Application for Orviglance, with the agency stating it is currently unable to approve the filing in its present form and requesting additional clinical data and product documentation.ACE: Future FDA Resolution Will Support Long-Term Prospects Despite Current Concerns
Ascelia Pharma's analyst price target has been revised to SEK 2.87 from SEK 4.28, with analysts citing updated assumptions on fair value, revenue growth and profit margins as the main drivers of the change. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on its New Drug Application for Orviglance.
ACE: FDA Type A Meeting Will Drive Reassessment Of Long-Term Upside
Analysts have cut their Ascelia Pharma price target to SEK 3.70 from SEK 8.50, citing updated assumptions around revenue growth, profit margins and a lower future P/E multiple that together point to a more cautious valuation framework. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter (CRL) from the U.S. FDA on its New Drug Application for Orviglance, with the agency requesting additional clinical data and product documentation.Recent updates
ACE: FDA Type A Meeting Will Shape Long-Term Upside Potential
Analysts have trimmed their price target on Ascelia Pharma from SEK 2.87 to SEK 2.40, reflecting updated assumptions around discount rates, profit expectations and future P/E levels. What's in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on the New Drug Application for Orviglance, with the agency stating it is currently unable to approve the filing in its present form and requesting additional clinical data and product documentation.ACE: Future FDA Resolution Will Support Long-Term Prospects Despite Current Concerns
Ascelia Pharma's analyst price target has been revised to SEK 2.87 from SEK 4.28, with analysts citing updated assumptions on fair value, revenue growth and profit margins as the main drivers of the change. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on its New Drug Application for Orviglance.ACE: FDA Type A Meeting Will Drive Reassessment Of Long-Term Upside
Analysts have cut their Ascelia Pharma price target to SEK 3.70 from SEK 8.50, citing updated assumptions around revenue growth, profit margins and a lower future P/E multiple that together point to a more cautious valuation framework. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter (CRL) from the U.S. FDA on its New Drug Application for Orviglance, with the agency requesting additional clinical data and product documentation.ACE: Rising Long-Term Prospects Will Outweigh Present Going Concern Risk
Analysts have revised their price target on Ascelia Pharma to SEK4.28 from SEK6.32, reflecting updated assumptions on the discount rate, revenue growth outlook, profit margin expectations, and future P/E multiples. What's in the News for Ascelia Pharma Ascelia Pharma scheduled an Analyst and Investor Day, described as "Ascelia Pharma AB (publ) Analyst/Investor Day," giving the market a dedicated forum to hear directly from management and review the company story.Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes drugs in rare oncology, with a focus on liver imaging and oral chemotherapy. What are the underlying business or industry changes driving this perspective?
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare, cancer related conditions. What are the underlying business or industry changes driving this perspective?We're Hopeful That Ascelia Pharma (STO:ACE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rentabilidad de los accionistas
| ACE | SE Biotechs | Mercado SE | |
|---|---|---|---|
| 7D | -3.6% | -3.8% | -2.8% |
| 1Y | -84.1% | 18.6% | 11.5% |
Rentabilidad vs. Industria: Los resultados de ACE fueron inferiores a los de la industria Swedish Biotechs, que obtuvo un rendimiento del 18.6% el año pasado.
Rentabilidad vs. Mercado: ACE obtuvo unos resultados inferiores a los del mercado Swedish, que fueron del 11.5% el año pasado.
Volatilidad de los precios
| ACE volatility | |
|---|---|
| ACE Average Weekly Movement | 24.0% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in SE Market | 10.9% |
| 10% least volatile stocks in SE Market | 2.9% |
Precio estable de las acciones: El precio de las acciones de ACE ha sido volátil durante los últimos 3 meses en comparación con el mercado Swedish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ACE ha aumentado de 14% a 24% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1999 | 10 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), empresa biotecnológica, se centra en tratamientos oncológicos huérfanos en Suecia. La empresa identifica, desarrolla y comercializa fármacos novedosos para atender necesidades no cubiertas de enfermedades oncológicas raras. Desarrolla Orviglance, un nuevo medicamento de diagnóstico sin gadolinio, que está en fase 3 de ensayo clínico para su uso en resonancias magnéticas del hígado; y Oncoral, un nuevo comprimido oral de quimioterapia con irinotecán, que está en fase 2 de ensayo clínico para el tratamiento del cáncer gástrico.
Resumen de fundamentos de Ascelia Pharma AB (publ)
| Estadísticas fundamentales de ACE | |
|---|---|
| Capitalización bursátil | SEK 83.06m |
| Beneficios(TTM) | -SEK 60.13m |
| Ingresos (TTM) | n/a |
¿Está ACE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ACE | |
|---|---|
| Ingresos | SEK 0 |
| Coste de los ingresos | SEK 0 |
| Beneficio bruto | SEK 0 |
| Otros gastos | SEK 60.13m |
| Beneficios | -SEK 60.13m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
Nov 05, 2026
| Beneficios por acción (BPA) | -0.45 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ACE a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/15 13:50 |
| Precio de las acciones al final del día | 2026/09/15 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ascelia Pharma AB (publ) está cubierta por 6 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | ABG Sundal Collier Sponsored |
| Lars Hevreng | Danske Bank |
| Maria Karlsson Osipova | DNB Carnegie Commissioned Research |